Computational comparison of two new fusion proteins for multiple sclerosis

Multiple sclerosis (MS), as one of the human autoimmune diseases, demyelinates the neurons of the central nervous system (CNS). Activation of the T cells which target the CNS antigens is the first autoimmune event in MS. Myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP) are tw...

Full description

Bibliographic Details
Main Authors: Nasrin Payab, Karim Mahnam, Mostafa Shakhsi-Niaei
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2018-01-01
Series:Research in Pharmaceutical Sciences
Subjects:
Online Access:http://www.rpsjournal.net/article.asp?issn=1735-5362;year=2018;volume=13;issue=5;spage=394;epage=403;aulast=Payab
id doaj-a36de7c11a234d2297f232cf04e24fd5
record_format Article
spelling doaj-a36de7c11a234d2297f232cf04e24fd52021-07-07T14:29:33ZengWolters Kluwer Medknow PublicationsResearch in Pharmaceutical Sciences1735-53621735-94142018-01-0113539440310.4103/1735-5362.236832Computational comparison of two new fusion proteins for multiple sclerosisNasrin PayabKarim MahnamMostafa Shakhsi-NiaeiMultiple sclerosis (MS), as one of the human autoimmune diseases, demyelinates the neurons of the central nervous system (CNS). Activation of the T cells which target the CNS antigens is the first autoimmune event in MS. Myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP) are two proteins of the myelin sheath and have been shown to be among the high antigens contributing to the pathogenesis of MS. Production of the drugs with high specificity for the immune system diseases is a concern for various researchers. Therefore, tolerogenic vaccines are considered as a new strategy for the treatment of MS by presenting specific antigens. This study aimed to design and compare two fusion proteins by a combination of two neuroantigens linked to interleukin-16 (IL-16) (MOG-Linker-MBP-IL16 and MBP-Linker-MOG-IL16) as vaccines for MS. In this study, at first two models MOG (aa 11-30) linked to MBP (aa 13-32) was made by Modeler 9.10 and simulated for 20 ns via Gromacs 5.1.1 package. Then simulated antigen domains connected to the N-terminal domain of IL-16 and obtained structures simulated for 50 ns. The results revealed that both constructs had stable structures and the linker could keep two antigenic fragments separate enough, preventing undesired interactions. While MOG-Linker-MBP-IL16 showed better solubility, more accessible surface areas, more flexibility of its IL-16 domain, and better functionality of its IL-16 domain as well as more specific cleavage of its related epitopes after endocytosis lead to a better presentation of its antigenic property.http://www.rpsjournal.net/article.asp?issn=1735-5362;year=2018;volume=13;issue=5;spage=394;epage=403;aulast=Payabfusion protein; mbp; mog; molecular dynamics simulation; multiple sclerosis; vaccine
collection DOAJ
language English
format Article
sources DOAJ
author Nasrin Payab
Karim Mahnam
Mostafa Shakhsi-Niaei
spellingShingle Nasrin Payab
Karim Mahnam
Mostafa Shakhsi-Niaei
Computational comparison of two new fusion proteins for multiple sclerosis
Research in Pharmaceutical Sciences
fusion protein; mbp; mog; molecular dynamics simulation; multiple sclerosis; vaccine
author_facet Nasrin Payab
Karim Mahnam
Mostafa Shakhsi-Niaei
author_sort Nasrin Payab
title Computational comparison of two new fusion proteins for multiple sclerosis
title_short Computational comparison of two new fusion proteins for multiple sclerosis
title_full Computational comparison of two new fusion proteins for multiple sclerosis
title_fullStr Computational comparison of two new fusion proteins for multiple sclerosis
title_full_unstemmed Computational comparison of two new fusion proteins for multiple sclerosis
title_sort computational comparison of two new fusion proteins for multiple sclerosis
publisher Wolters Kluwer Medknow Publications
series Research in Pharmaceutical Sciences
issn 1735-5362
1735-9414
publishDate 2018-01-01
description Multiple sclerosis (MS), as one of the human autoimmune diseases, demyelinates the neurons of the central nervous system (CNS). Activation of the T cells which target the CNS antigens is the first autoimmune event in MS. Myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP) are two proteins of the myelin sheath and have been shown to be among the high antigens contributing to the pathogenesis of MS. Production of the drugs with high specificity for the immune system diseases is a concern for various researchers. Therefore, tolerogenic vaccines are considered as a new strategy for the treatment of MS by presenting specific antigens. This study aimed to design and compare two fusion proteins by a combination of two neuroantigens linked to interleukin-16 (IL-16) (MOG-Linker-MBP-IL16 and MBP-Linker-MOG-IL16) as vaccines for MS. In this study, at first two models MOG (aa 11-30) linked to MBP (aa 13-32) was made by Modeler 9.10 and simulated for 20 ns via Gromacs 5.1.1 package. Then simulated antigen domains connected to the N-terminal domain of IL-16 and obtained structures simulated for 50 ns. The results revealed that both constructs had stable structures and the linker could keep two antigenic fragments separate enough, preventing undesired interactions. While MOG-Linker-MBP-IL16 showed better solubility, more accessible surface areas, more flexibility of its IL-16 domain, and better functionality of its IL-16 domain as well as more specific cleavage of its related epitopes after endocytosis lead to a better presentation of its antigenic property.
topic fusion protein; mbp; mog; molecular dynamics simulation; multiple sclerosis; vaccine
url http://www.rpsjournal.net/article.asp?issn=1735-5362;year=2018;volume=13;issue=5;spage=394;epage=403;aulast=Payab
work_keys_str_mv AT nasrinpayab computationalcomparisonoftwonewfusionproteinsformultiplesclerosis
AT karimmahnam computationalcomparisonoftwonewfusionproteinsformultiplesclerosis
AT mostafashakhsiniaei computationalcomparisonoftwonewfusionproteinsformultiplesclerosis
_version_ 1721315288310349824